Skip to main content

Advertisement

SpringerLink
Log in

Clinical report on transarterial neoadjuvant chemotherapy of malignant fibrous histiocytoma in soft tissue

  • Research Article
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

Purpose

To review the experience in transarterial neoadjuvant chemotherapy of malignant fibrous histiocytoma (MFH) in soft tissue and to analyze the factors related to prognosis of MFH in soft tissue.

Methods

Between September 1999 and December 2011, 101 cases of MFH in soft tissue patients treated by transarterial administration of Cisplatin, Adriamycin and Norcantharidin were divided into primary group and recurrent group, and the clinical documents were reviewed. Nine factors that might affect prognosis such as age, sex, tumor size, tumor site, tumor infiltration depth, recurrence if any, pathological type, histologic grade and histologic response of chemotherapy were analyzed statistically.

Results

The 5-year relapse-free survival rate and the overall survival rate were 70.5 and 75.0 %, respectively, in the primary group; 56.1 and 57.9 %, respectively, in the recurrent group. Univariate analysis (log-rank test) showed that the factors affecting the prognosis were age (P = 0.03), tumor size (P = 0.01), pelvic tumor (P = 0.02), recurrence if any (P = 0.004), histologic grade (P = 0.01), and histologic response to chemotherapy (P = 0.007). Multivariate analysis showed that the major factors affecting prognosis were pelvic tumor (P = 0.01), tumor size (P = 0.002), histologic grade (P = 0.002), recurrence if any (P = 0.0004), and histologic response to chemotherapy (P = 0.008).

Conclusion

Transarterial neoadjuvant chemotherapy can significantly increase the curative efficacy of chemotherapy and survival rate in MFH treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. O’Brien JE, Stout AP (1964) Malignant fibrous xanthomas. Cancer 11:1445–1455

    Article  Google Scholar 

  2. Fletcher CDM, Unni KK, Mertens F (eds) (2002) Pathology and genetics of tumours of soft tissues and bone. World Health Organization classification of tumors. IARC Press, Lyon

  3. Enzinger FM, Weiss SW (2001) Soft tissue tumors, 4th edn. Mosby, St. Louis

    Google Scholar 

  4. Peiper M, Zurakowski D, Knoefel WT, Izbicki JR (2004) Malignant fibrous histiocytoma of the extremities and trunk: an institutional review. Surgery 135(1):59–66

    Article  PubMed  Google Scholar 

  5. Rosen G, Caparros B, Huvos AG, Kosloff C, Nirenberg A, Cacavio A, Marcove RC, Lane JM, Mehta B, Urban C (1982) Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer 49:1221–1230

    Article  PubMed  CAS  Google Scholar 

  6. Lehnhardt M, Daigeler A, Homann HH, Schwaiberger V, Goertz O, Kuhnen C, Steinau HU (2009) MFH revisited: outcome after surgical treatment of undifferentiated pleomorphic or not otherwise specified (NOS) sarcomas of the extremities—an analysis of 140 patients. Langenbecks Arch Surg 394:313–320

    Article  PubMed  Google Scholar 

  7. Belal A, Kandil A, Allam A, Khafaga Y, El-Husseiny G, El-Enbaby A, Memon M, Younge D, Moreau P, Gray A, Schultz H (2002) Malignant fibrous histiocytoma: a retrospective study of 109 cases. Am J Clin Oncol 25(1):16–22

    Article  PubMed  Google Scholar 

  8. Guang-xue LI, Wei GUO (2011) Analysis of therapeutic strategies and prognostic factors of malignant fibrous histiocytoma of soft tissue. Chin J Surg 49(11):974–977

    Google Scholar 

  9. Gibbs JF, Huang PP, Lee RJ, McGrath B, Brooks J, McKinley B, Driscoll D, Kraybill WG (2001) Malignant fibrous histiocytoma: an institutional review. Cancer Invest 19(1):23–27

    Article  PubMed  CAS  Google Scholar 

  10. Bacci G, Ferrari S, Picci P et al (1996) Neoadjuvant chemotherapy in malignant fibrous histiocytoma of the limbs: 10 years of experience (1983–1992) at the Rizzoli Orthopedic Institute. Minerva Med 87(4):135–146

    PubMed  CAS  Google Scholar 

  11. Atalar H, Başarir K, Yildiz Y, Sağlik Y (2007) Prognostic factors in patients with malignant fibrous histiocytoma of the extremities. Acta Orthop Traumatol Turc 41(4):271–276

    PubMed  Google Scholar 

  12. Hugate RR, Wilkins RM, Cynthia M et al (2008) Intraarterial chemotherapy for extremity osteosarcoma and MFH in adults. Clin Orthop Relat Res 6(466):1292–1301

    Article  Google Scholar 

  13. Gutierrez JC, Perez EA, Franceschi D, Moffat FL Jr, Livingstone AS, Koniaris LG (2007) Outcomes for soft-tissue sarcoma in 8,249 cases from a large state cancer registry. J Sung Res 141(1):105–114

    Article  Google Scholar 

  14. Ham SJ, Hoekstra HJ, van der Graaf WT, Kamps WA, Molenaar WM, Schraffordt Koops H (1996) The value of high-dose methotrexate-based neoadjuvant chemotherapy in malignant fibrous histiocytoma of bone. J Clin Oncol 14(2):490–496

    PubMed  CAS  Google Scholar 

  15. Bacci G, Springfield D, Capanna R, Picci P, Bertoni F, Campanacci M (1985) Adjuvant chemotherapy for malignant fibrous histiocytoma in the femur and tibia. J Bone Joint Surg [Am] 67:620–625

    CAS  Google Scholar 

  16. Picci P, Bacci G, Ferrari S, Mercuri M (1997) Neoadjuvant chemotherapy in malignant fibrous histiocytoma of bone and in osteosarcoma located in the extremities: analogies and differences between the two tumors. Ann Oncol 8(11):1107–1115

    Article  PubMed  CAS  Google Scholar 

  17. Nooij MA, Whelan J, Bramwell VH, Taminiau AT, Cannon S, Hogendoorn PC, Pringle J, Uscinska BM, Weeden S, Kirkpatrick A, Glabbeke M, European Osteosarcoma Intergroup (2005) Doxorubicin and cisplatin chemotherapy in high-grade spindle cell sarcomas of the bone, other than osteosarcoma or malignant fibrous histiocytoma: a European Osteosarcoma Intergroup Study. Eur J Cancer 41(2):225–230

    Article  PubMed  CAS  Google Scholar 

  18. Bramwell VH, Steward WP, Nooij M, Whelan J, Craft AW, Grimer RJ, Taminau AH, Cannon SR, Malcolm AJ, Hogendoorn PC, Uscinska B, Kirkpatrick AL, Machin D, Van Glabbeke MM (1999) Neoadjuvant chemotherapy with doxorubicin and cisplatin in malignant fibrous histiocytoma of bone: a European Osteosarcoma Intergroup study. J Clin Oncol 17(10):3260–3269

    PubMed  CAS  Google Scholar 

  19. Shiba M, Takatera H, Fujii T, Tokizane T, Shimizu K, Tushima J (2004) Intraarterial chemotherapy with bladder preservation in patients with invasive bladder carcinoma. Hinyokika Kiyo 50(1):15–19

    PubMed  Google Scholar 

  20. Bacci G, Ruggieri P, Picci P, Mercuri M, Ferraro A, Tella G, Ferrari S, Bertoni F, Comandone A (1996) Intra-arterial versus intravenous cisplatinum (in addition to systemic Adriamycin and high dose methotrexate) in the neoadjuvant treatment of osteosarcoma of the extremities. results of a randomized study. J Chemother 8(1):70–81

    PubMed  CAS  Google Scholar 

  21. Yang PY, Chen MF, Kao YH, Hu DN, Chang FR, Wu YC (2011) Norcantharidin induces apoptosis of breast cancer cells: involvement of activities of mitogen activated protein kinases and signal transducers and activators of transcription. Toxicol In Vitro 25(3):699–707

    Article  PubMed  Google Scholar 

  22. Mack P, Ha XF, Cheng LY (1996) Efficacy of intra-arterial norcantharidin in suppressing tumour 14C-labelled glucose oxidative metabolism in rat Morris Hepatoma. HPB Surg 10(2):65–72

    Article  PubMed  CAS  Google Scholar 

  23. Salo JC, Lewis JJ, Woodruff JM, Leung DH, Brennan MF (1999) Malignant fibrous histiocytoma of the extremity. Cancer 85:1765–1772

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Department of Orthopedics, 307 Hospital of PLA, No. 8 East Street, Fengtai District, Beijing, 100071, China

    Jun Guo, Qiu Cui, Cheng Liu, Jiahong Sui, Ning Jiang, Ju Zhou & Dingfeng Li

  2. Biomedical Engineering Center, Beijing University of Technology, Beijing, 100022, China

    Yanjun Zeng

Authors
  1. Jun Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Qiu Cui
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Cheng Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jiahong Sui
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ning Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ju Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Dingfeng Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yanjun Zeng
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yanjun Zeng.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Guo, J., Cui, Q., Liu, C. et al. Clinical report on transarterial neoadjuvant chemotherapy of malignant fibrous histiocytoma in soft tissue. Clin Transl Oncol 15, 370–375 (2013). https://doi.org/10.1007/s12094-012-0933-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-012-0933-9

Keywords

Search

Navigation